Larimar Therapeutics, Inc. SEC filings LRMR
Larimar Therapeutics, Inc. has 696 filings in SEC EDGAR's recent list, going back to Aug 28, 2006. Its latest annual report, Form ARS, was filed on Apr 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 24, 2024 | — |
| CORRESP | Letter to the SEC | May 22, 2024 | — |
| UPLOAD | Letter from the SEC | May 16, 2024 | — |
| EFFECT | Filing | Nov 21, 2022 | — |
| CORRESP | Letter to the SEC | Nov 18, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2022 | — |
| EFFECT | Filing | Sep 1, 2020 | — |
| CORRESP | Letter to the SEC | Aug 31, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2020 | — |
| EFFECT | Filing | Jul 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 13, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2020 | — |
| D | Filing | Jun 10, 2020 | — |
| D | Filing | Jun 10, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2020 | — |
| CORRESP | Letter to the SEC | Apr 27, 2020 | — |
| PRER14A | Filing | Apr 27, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2020 | — |
| CORRESP | Letter to the SEC | Apr 10, 2020 | — |
| PRER14A | Filing | Apr 10, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2020 | — |
| EFFECT | Filing | Nov 20, 2018 | — |
| CORRESP | Letter to the SEC | Nov 16, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2018 | — |
| EFFECT | Filing | Aug 23, 2017 | — |
| CORRESP | Letter to the SEC | Aug 21, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 14, 2017 | — |
| EFFECT | Filing | Jan 22, 2015 | — |
| CT ORDER | Filing | Jun 23, 2014 | — |
| CORRESP | Letter to the SEC | Jun 20, 2014 | — |
| EFFECT | Filing | Jun 18, 2014 | — |
| CERTNAS | Auto-generated paper document | Jun 18, 2014 | — |
| 8-A12B | Filing | Jun 18, 2014 | — |
| CORRESP | Letter to the SEC | Jun 16, 2014 | — |
| CORRESP | Letter to the SEC | Jun 16, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 27, 2014 | — |
| DRS/A | Filing | Mar 14, 2014 | — |
| UPLOAD | Letter from the SEC | Feb 28, 2014 | — |
| DRS | Filing | Jan 31, 2014 | — |
| D | Filing | Dec 5, 2012 | — |
| D | Filing | Aug 28, 2012 | — |
| D | Filing | Jul 12, 2011 | — |
| D/A | Filing | Mar 2, 2010 | — |
| D | Filing | Mar 1, 2010 | — |
| REGDEX | Auto-generated paper document | Nov 3, 2008 | — |
| REGDEX | Auto-generated paper document | Jan 3, 2008 | — |
| REGDEX | Auto-generated paper document | Aug 28, 2006 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LRMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bala Cynwyd, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374690
- Former names
- ZAFGEN, INC. (until May 19, 2020); ZAFGEN INC (until Nov 3, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.